Fiasp (insulin aspart) for the Treatment of Type 1 and Type 2 Diabetes

Discovered and developed by Novo Nordisk, Fiasp ® (insulin aspart) is a fast-acting insulin analogue indicated for the treatment of adults with Type 1 and Type 2 diabetes.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news